TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34019819
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 intravenous), carboplatin (area under the concentration–time curve 6 mg/mL per min intravenous), trastuzumab (subcutaneous 600 mg fixed dose), and pertuzumab (intravenous 840 mg loading dose, 420 mg maintenance doses)
Study: 34019819
Drug: Trastuzumab and
Normalized name: pertuzumab and trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab and pertuzumab (with letrozole or tamoxifen for hormone receptor-positive patients)
Study: 32755237
Drug: Allogeneic growth
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic growth factors injection
Study: 32755237
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% injection
Study: 34530020
Drug: Omalizumab plus
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab plus background nasal mometasone therapy for 28 weeks
Study: 34530020
Drug: Omalizumab discontinuation
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab discontinuation
Study: 35696023
Drug: Collagen Peptide
Normalized name: Procollagen peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen Peptide (CP) at 5.0 g/day for 3 months
Study: 35696023
Drug: Collagen Peptide
Normalized name: Procollagen peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen Peptide Fermented with Aspergillus sojae (FCP) at 5.0 g/day for 3 months
Study: 35696023
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) at 5.0 g/day for 3 months
Study: 33429063
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg sc)
Study: 34062085
Drug: Qingrun yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingrun yogurt (250 g) once daily for 12 weeks
Study: 33277285
Drug: G-CSF +
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF + CA/CY/TBI
Study: 33788456
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus medication (flunarizine hydrochloride capsule 10 mg/day)
Study: 33788456
Drug: Medication (flunarizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (flunarizine hydrochloride capsule 10 mg/day)
Study: 35609291
Drug: Intensive physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive physical therapy (twice daily coached breathing exercises for 2 days and 30 minutes of daily supervised rehabilitation over the first 5 postoperative days)
Study: 33761894
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine 0.2 mg with sham QLB (Group IT)
Study: 33761894
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine 0.2 mg and bilateral QLB with 0.25% bupivacaine 25 ml in each side (Group IT+QLB)
Study: 33761894
Drug: Bilateral QLB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral QLB with 0.25% bupivacaine 25 ml in each side (Group QLB)
Study: 34520536
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy before aerobic exercises, three sessions per week for 12 weeks
Study: 34520536
Drug: Aerobic exercises
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercises three times weekly for 12 weeks (Control group)
Study: 35766558
Drug: PN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN with iron sucrose 100 μg/kg/d (Iron-1)
Study: 35766558
Drug: PN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN with iron sucrose 200 μg/kg/d (Iron-2)
Study: 35766558
Drug: PN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN with iron sucrose 300 μg/kg/d (Iron-3)
Study: 35766558
Drug: PN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN with iron sucrose 400 μg/kg/d (Iron-4)
Study: 34695232
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg vaginal misoprostol
Study: 34695232
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg vaginal misoprostol
Study: 33559272
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation with oral polyethylene glycol (PEG) solution
Study: 35165727
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate 200 mg once daily for 6 days (3 days orally and 3 days intravenously)
Study: 32422956
Drug: 52 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52 mL/day of EVOO
Study: 32422956
Drug: DieTBra +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DieTBra + 52 mL/day of EVOO
Study: 35908159
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion (CIV) of enoxaparin 40 mg per day for 72 hours
Study: 35908159
Drug: Subcutaneous bolus
Normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous bolus (SCB) injection of enoxaparin 40 mg per day for 72 hours
Study: 35908159
Drug: Both CIV
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both CIV and SCB administration of enoxaparin after 72 hours
Study: 34783727
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration therapy (amplitude of 3mm, frequency of 20Hz, 12 sessions, 5 bouts of 120 seconds with 60s rest intervals, 6 days/week for 2 weeks)
Study: 32868548
Drug: Prospective pharmacist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospective pharmacist verification process on all ED discharge prescriptions
Study: 34968373
Drug: Full vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full vaccination with Pfizer-BioNTech vaccine (2 doses, ≥14 days after the second dose)
Study: 34968373
Drug: Partially vaccinated
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially vaccinated (1 dose or 2 doses <14 days)
Study: 33332232
Drug: Full body
Normalized name: MENTHOL 10.5 g in 100 mL TOPICAL LIQUID [Tidl Full Body Pain Relief Cryotherapy Spray.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full body photobiomodulation therapy (PBMT) with a dose of 6.9 J/cm2, irradiance of 46.17 mW/cm2, 5 min irradiation
Study: 35226113
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) following standard epineural nerve repair
Study: 35758652
Drug: Suvratoxumab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvratoxumab (monoclonal antibody targeting S. aureus alpha-toxin)
Study: 33150590
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg for 3 days)
Study: 33103229
Drug: Pulse methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulse methylprednisolone therapy (30 mg/kg/d for five days followed by oral steroids 1 mg/kg tapered over 5-6 weeks)
Study: 33103229
Drug: Intramuscular adrenocorticotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular adrenocorticotropic hormone (ACTH) therapy
Study: 32423392
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula (SF) - cow's milk based infant formula with DHA (17 mg/100 kcal) and ARA (25 mg/100 kcal); 1.9 g protein/100 kcal; 1.2 mg Fe/100 kcal
Study: 34187832
Drug: Seroprevalence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seroprevalence of anti-SARS-CoV-2 antibodies
Study: 33619370
Drug: Topical ShA9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ShA9
Study: 35039272
Drug: Cooling blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling blood detoxification decoction plus traditional Chinese medicine (TCM) care
Study: 35039272
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment plus routine nursing
Study: 34585780
Drug: Single 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5 mg dose of zoledronate
Study: 34585780
Drug: 5-yearly doses
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-yearly doses of 2.5 mg zoledronate
Study: 34585780
Drug: Redosing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Redosing with 1 mg zoledronate
Study: 34585780
Drug: Redosing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Redosing with 2.5 mg zoledronate
Study: 33940213
Drug: Maintaining low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maintaining low-dose ICS/LABA (G1)
Study: 33940213
Drug: Reducing ICS/LABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reducing ICS/LABA to once daily (G3)
Study: 33407787
Drug: Inhibitory repetitive
Normalized name: Gastric inhibitory polypeptide
DrugBank: Gastric inhibitory polypeptide (DB15217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitory repetitive transcranial magnetic stimulation (r-TMS) applied over the left intact parietal cortex followed by visual scanning treatment
Study: 33407787
Drug: Placebo stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo stimulation (SHAM control) followed by visual scanning treatment
Study: 35769675
Drug: Fuji triage
Normalized name: Gibberella fujikuroi
DrugBank: Gibberella fujikuroi (DB15511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuji triage capsule, GC, Belgium
Study: 34904623
Drug: Traditional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatments
Study: 32070681
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of PCV7 or HibCV at 15 months of age
Study: 34042412
Drug: Placebo SWD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SWD treatment (Control)
Study: 32507842
Drug: Pharmacologic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacologic intervention for hyperlipidaemia with LDL-C level of 3.36 mmol/l (130 mg/dl) as the threshold.
Study: 32507842
Drug: Pharmacologic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacologic intervention for hyperglycaemia with fasting plasma glucose of ≥5.3 mmol/l (95 mg/dl) and 2-hour postprandial glucose level of 7.8 mmol/l (140 mg/dl) as the threshold.
Study: 32507842
Drug: Initiating treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiating treatment for hypertension at blood pressure of ≥130/≤89 mmHg or ≤139/≥85 mmHg.
Study: 32507842
Drug: Pharmacologic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacologic intervention for hypertensive patients (BP ≥160/≥100 mmHg) with total cholesterol of 6.5 mmol/l (251.35 mg/dl) or higher.
Study: 35589454
Drug: Adjunctive injustice
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive injustice writing intervention
Study: 33839076
Drug: Levosimendan (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.075 to 0.1 ug/kg/min for 24 h, once weekly for 6 weeks)
Study: 38704973
Drug: Exposure-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based treatment for perfectionism (ETP)
Study: 33407337
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of Hyaluronic acid after arthroscopic lateral release.
Study: 35666545
Drug: Single-dose topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose topical dexamethasone
Study: 34685778
Drug: Spironolactone treatment
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone treatment (verum)
Study: 35837707
Drug: Denosumab (short-course,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (short-course, varying from 3 to 6 doses)
Study: 32524511
Drug: Pharmacist-led medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacist-led medicines optimisation clinic
Study: 35674762
Drug: Trifarotene 0.005%
Normalized name: TRIFAROTENE 0.005% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifarotene 0.005% cream
Study: 34254673
Drug: Cenobamate (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate (median dose 200 mg, range 50–400 mg)
Study: 33040465
Drug: TDF/FTC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC plus vitamin D3 and calcium supplementation (400 units of vitamin D3 and 1200 mg of elemental calcium/day)
Study: 34021020
Drug: GAD-alum therapy
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum therapy with vitamin D supplementation (4 μg GAD-alum intralymphatic injections, 2,000 IE vitamin D daily for 120 days)
Study: 34021020
Drug: GAD-alum therapy
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum therapy with vitamin D supplementation in HLA DR3-DQ2 genotype (n = 29)
Study: 34021020
Drug: GAD-alum therapy
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum therapy with vitamin D supplementation
Study: 35283526
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg once daily for 6 weeks
Study: 35283526
Drug: Rupatadine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 10 mg once daily for 6 weeks
Study: 34876454
Drug: TNF receptor‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF receptor‐1
Study: 34876454
Drug: TNF receptor‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF receptor‐2
Study: 34876454
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of TNF receptor‐1 (≥2992 ng/ml)
Study: 34876454
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of TNF receptor‐2 (≥11,394 ng/ml)
Study: 34876454
Drug: Lower three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower three quartiles of TNF receptor‐1
Study: 34876454
Drug: Lower three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower three quartiles of TNF receptor‐2
Study: 33978597
Drug: PEARS intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEARS intervention with low glycemic index dietary intervention and exercise prescription
Study: 32856448
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA (3 g in 50 ml of saline solution)
Study: 32856448
Drug: Intravenous +
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous + topical TXA (3 g topical + 2 g in 100 ml of saline solution intravenously)
Study: 39443013
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric derisomaltose (FDI)
Study: 33941146
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative care (CC)
Study: 34591079
Drug: TAC 10
Normalized name: Sustac 10 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC 10 mg/mL, 24 hours before surgery
Study: 34591079
Drug: TAC 10
Normalized name: Sustac 10 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC 10 mg/mL, 1 hour before surgery
Study: 34591079
Drug: TAC 40
Normalized name: Congestac 400mg-60mg Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC 40 mg/mL, 24 hours before surgery
Study: 34591079
Drug: TAC 40
Normalized name: Congestac 400mg-60mg Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC 40 mg/mL, 1 hour before surgery
Study: 32739562
Drug: Health Information
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health Information Preferences (HIPs) regarding diagnosis and treatment details
Study: 34547529
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg aflibercept every 16 weeks (2Q16)
Study: 34547529
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg aflibercept every 8 weeks as needed (2Q8PRN)
Study: 33510892
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg Curcuma longa
Study: 33510892
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg Curcuma longa
Study: 34008052
Drug: Once-daily inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily inhaled budesonide
Study: 34008052
Drug: Twice-daily inhaled
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily inhaled budesonide
Study: 32448136
Drug: CareDose 4D
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CareDose 4D low-dose CT combined with Karl 3D technology
Study: 34279646
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate therapy (40-75 mg/kg)
Study: 34279646
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium therapy (2011-2016)
Study: 34279646
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium therapy (2017-2019)
Study: 34279646
Drug: Additional albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional albuterol use
Study: 34279646
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium therapy in children with a disposition PRAM score of 3 or lower
Study: 32189664
Drug: 40 HBOTs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 HBOTs at 150 kPa/60 minutes, once daily, 5 days per week for 8 weeks
Study: 32109425
Drug: Gefapixant 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefapixant 7.5 mg
Study: 32109425
Drug: Gefapixant 20
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 20 mg
Study: 32109425
Drug: Gefapixant 50
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 50 mg
Study: 35679950
Drug: Vonoprazan triple
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan triple therapy (20 mg vonoprazan twice daily; 1 g amoxicillin 3 times daily)
Study: 35679950
Drug: Vonoprazan dual
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan dual therapy (20 mg vonoprazan twice daily; 1 g amoxicillin 3 times daily)
Study: 35679950
Drug: Lansoprazole triple
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole triple therapy (30 mg lansoprazole; 1 g amoxicillin; 500 mg clarithromycin)
Study: 35679950
Drug: Vonoprazan triple
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan triple therapy
Study: 35679950
Drug: Vonoprazan dual
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan dual therapy
Study: 35679950
Drug: Lansoprazole triple
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole triple therapy
Study: 35750038
Drug: Atezolizumab 840
Normalized name: atezolizumab 840 MG in 14 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 840 mg every 2 weeks with nab-paclitaxel and anthracycline-based chemotherapy
Study: 35750038
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with nab-paclitaxel and anthracycline-based chemotherapy
Study: 35750038
Drug: Atezolizumab 840
Normalized name: atezolizumab 840 MG in 14 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 840 mg every 2 weeks with nab-paclitaxel and anthracycline-based chemotherapy (PD-L1-positive population)
Study: 35750038
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with nab-paclitaxel and anthracycline-based chemotherapy (PD-L1-positive population)
Study: 35750038
Drug: Atezolizumab 840
Normalized name: atezolizumab 840 MG in 14 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 840 mg every 2 weeks
Study: 32977404
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2000 mg DHA + 400 mg EPA/day)
Study: 32977404
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of curcumin and fish oil
Study: 33473019
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drug (NSAID)
Study: 33473019
Drug: NSAID and
Normalized name: methenamine
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAID and antihistaminic drug combination
Study: 93178847
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa therapy for 26 weeks
Study: 36494045
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi intervention, remotely delivered, twice a week for 12 weeks
Study: 36494045
Drug: Wellness control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wellness control condition, remotely delivered, twice a week for 12 weeks